ATE443724T1 - Antikrebs-antikörper mit reduzierter komplementfixierung - Google Patents
Antikrebs-antikörper mit reduzierter komplementfixierungInfo
- Publication number
- ATE443724T1 ATE443724T1 AT05701002T AT05701002T ATE443724T1 AT E443724 T1 ATE443724 T1 AT E443724T1 AT 05701002 T AT05701002 T AT 05701002T AT 05701002 T AT05701002 T AT 05701002T AT E443724 T1 ATE443724 T1 AT E443724T1
- Authority
- AT
- Austria
- Prior art keywords
- complement fixation
- cancer antibodies
- reduced complement
- cell
- modified antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53834804P | 2004-01-22 | 2004-01-22 | |
PCT/EP2005/000428 WO2005070967A2 (en) | 2004-01-22 | 2005-01-18 | Anti-cancer antibodies with reduced complement fixation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE443724T1 true ATE443724T1 (de) | 2009-10-15 |
Family
ID=34807180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05701002T ATE443724T1 (de) | 2004-01-22 | 2005-01-18 | Antikrebs-antikörper mit reduzierter komplementfixierung |
Country Status (12)
Country | Link |
---|---|
US (5) | US7432357B2 (de) |
EP (1) | EP1706428B1 (de) |
JP (1) | JP4987484B2 (de) |
AT (1) | ATE443724T1 (de) |
AU (1) | AU2005206277B2 (de) |
CA (1) | CA2553883C (de) |
DE (1) | DE602005016773D1 (de) |
DK (1) | DK1706428T3 (de) |
ES (1) | ES2330860T3 (de) |
PL (1) | PL1706428T3 (de) |
PT (1) | PT1706428E (de) |
WO (1) | WO2005070967A2 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
JP4309662B2 (ja) | 2001-05-03 | 2009-08-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍特異的組換え抗体およびその使用 |
DE60232265D1 (de) * | 2001-10-25 | 2009-06-18 | Genentech Inc | Glycoprotein-zusammensetzungen |
MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
PT1699822E (pt) * | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
PT1706428E (pt) | 2004-01-22 | 2009-12-29 | Merck Patent Gmbh | Anticorpos anticancerígenos com fixação de complemento reduzida |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
EP3489257A1 (de) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii-rezeptor-polypeptide, verfahren und zusammensetzungen |
EP1819728B1 (de) * | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7-varianten mit reduzierter immunogenität |
JP5261187B2 (ja) | 2005-11-23 | 2013-08-14 | アクセルロン ファーマ, インコーポレイテッド | アクチビン−ActRIIaアンタゴニストおよび骨成長を促進するための使用 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
PL1966238T3 (pl) | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Warianty interleukiny-12p40 o polepszonej stabilności |
CA2638804C (en) * | 2006-03-03 | 2017-02-28 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
FR2906808B1 (fr) * | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI667038B (zh) | 2007-02-09 | 2019-08-01 | 美商艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
EP2207562B1 (de) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonisten und verfahren zur verringerung oder inhibierung der fsh-sekretion |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
FI3750552T3 (fi) | 2008-08-14 | 2023-07-25 | Acceleron Pharma Inc | Gdf-loukkuja |
CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
KR20120030383A (ko) * | 2009-04-22 | 2012-03-28 | 메르크 파텐트 게엠베하 | 변형된 FcRn 결합 자리를 갖는 항체 융합 단백질 |
MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
AU2010263182B2 (en) | 2009-06-12 | 2016-05-12 | Acceleron Pharma Inc. | Truncated ActRIIB-Fc fusion proteins |
CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
CN103347894B (zh) | 2010-06-19 | 2017-05-10 | 纪念斯隆-凯特林癌症中心 | 抗gd2抗体 |
JP5534977B2 (ja) * | 2010-06-29 | 2014-07-02 | 東レ・ダウコーニング株式会社 | 硬化性オルガノポリシロキサン組成物および光半導体装置 |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
FR2971250A1 (fr) | 2011-02-07 | 2012-08-10 | Univ Nantes | Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese |
JP5926791B2 (ja) | 2011-03-29 | 2016-05-25 | ロシュ グリクアート アーゲー | 抗体Fc変種 |
WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
EP4218811A1 (de) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Verfahren zur behandlung von gd2-positiven krebs |
AU2013288641B2 (en) | 2012-07-13 | 2017-07-06 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
EP2914277B1 (de) | 2012-11-02 | 2017-09-13 | Celgene Corporation | Activin-actrii-antagonisten und verwendungen zur behandlung von knochen- und anderen erkrankungen |
KR102207859B1 (ko) | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | 고 친화도 항-gd2 항체 |
US10669328B2 (en) | 2013-11-12 | 2020-06-02 | Ogd2 Pharma | Human IgG1 derived antibody with pro-apoptotic activity |
US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
PT3071220T (pt) | 2013-11-21 | 2020-02-03 | Apeiron Biologics Ag | Preparações para tratamento de um cancro positivo para gd2 |
WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MD4801C1 (ro) | 2014-12-03 | 2022-10-31 | Celgene Corporation | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice |
WO2016130918A1 (en) * | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
BR112019017256A2 (pt) * | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics Inc | proteínas de ligação gd2, nkg2d e cd16 |
RU2663104C1 (ru) * | 2017-07-13 | 2018-08-01 | Общество с ограниченной ответственностью "Реал Таргет" | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
MX2021005808A (es) | 2018-11-20 | 2021-07-02 | Univ Cornell | Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer. |
GB201917487D0 (en) | 2019-11-29 | 2020-01-15 | Oxular Ltd | Methods for the treatment of retinoblastoma |
IL299504A (en) | 2020-07-06 | 2023-02-01 | Eusa Pharma Uk Ltd | A method for treating GD2-positive cancer |
CN117677695A (zh) * | 2021-03-24 | 2024-03-08 | 拜奥卡德联合股份公司 | 与gd2特异性结合的单克隆抗体 |
WO2023172968A1 (en) * | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5679543A (en) * | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (de) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Geänderte antikörper |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
ES2054753T3 (es) | 1987-09-02 | 1994-08-16 | Ciba Geigy Ag | Conjugados de citoquinas con inmunoglobulinas. |
US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
ES2058199T3 (es) | 1987-09-23 | 1994-11-01 | Bristol Myers Squibb Co | Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih. |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
ATE228566T1 (de) | 1989-09-20 | 2002-12-15 | Abbott Lab | Verfahren zur herstellung von fusionsproteinen |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
JPH07507440A (ja) | 1990-03-02 | 1995-08-24 | レプリゲン・コーポレーション | 結合親和性を高めた抗体構築物 |
CA2082804A1 (en) | 1990-07-27 | 1992-01-28 | Theodore Maione | Methods and compositions for treatment of angiogenic diseases |
AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
CA2095842A1 (en) | 1990-11-09 | 1992-05-10 | Stephen D. Gillies | Bridging antibody fusion constructs |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
WO1992010755A1 (en) | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
EP0519596B1 (de) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
WO1993005169A1 (en) | 1991-08-30 | 1993-03-18 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
WO1993025673A1 (en) * | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
EP0671926B1 (de) * | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunmodulierende peptide |
DE4228839A1 (de) * | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
US5837821A (en) * | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
WO1994025609A1 (en) | 1993-04-28 | 1994-11-10 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6410008B1 (en) * | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6972323B1 (en) * | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
CA2693296C (en) | 1997-12-08 | 2013-09-10 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2267263T3 (es) * | 1998-04-15 | 2007-03-01 | Emd Lexigen Research Center Corp. | Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo. |
CZ20003817A3 (cs) * | 1998-04-17 | 2002-08-14 | Lexigen Pharmaceuticals Corporation | Léčivo pro indukci cytocidní imunitní odpovědi |
US6284536B1 (en) * | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
EP1088888A4 (de) | 1998-05-14 | 2005-03-16 | Merck Patent Gmbh | Fusionierte proteine |
GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
DK1107989T3 (da) * | 1998-08-25 | 2010-05-25 | Merck Patent Gmbh | Ekspression og eksport af angiostatin og endostatin som immunfusiner |
US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
CZ20012406A3 (cs) * | 1999-01-07 | 2002-03-13 | Lexigen Pharmaceuticals, Corp. | Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů |
US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (de) * | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | VERFAHREN ZUR KONTROLLE DER AKTIVITäT VON IMMUNOLOGISCH FUNKTIONELLEM MOLEKüL |
DE60035871T2 (de) * | 1999-05-19 | 2008-06-05 | Merck Patent Gmbh | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
JP5179689B2 (ja) * | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
US20020019342A1 (en) * | 2000-05-12 | 2002-02-14 | Robert Bayer | In vitro modification of glycosylation patterns of recombinant glycopeptides |
DE10117248A1 (de) * | 2000-05-31 | 2002-10-10 | Mg Technologies Ag | Verfahren zum Erzeugen von Propylen aus Methanol |
US7517526B2 (en) * | 2000-06-29 | 2009-04-14 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US20020114781A1 (en) * | 2000-09-14 | 2002-08-22 | Strom Terry B. | Modulation of IL-2- and IL-15-mediated T cell responses |
US7737258B2 (en) * | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
MXPA03006294A (es) * | 2001-01-18 | 2003-09-16 | Merck Patent Gmbh | Proteinas de fusion disfuncionales con actividad glucocerebrosidasa. |
PL362324A1 (en) * | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
EP1366455B1 (de) * | 2001-02-19 | 2008-07-02 | MERCK PATENT GmbH | Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität |
BR0207854A (pt) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
JP4309662B2 (ja) * | 2001-05-03 | 2009-08-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍特異的組換え抗体およびその使用 |
MXPA04005266A (es) * | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
PT1706428E (pt) | 2004-01-22 | 2009-12-29 | Merck Patent Gmbh | Anticorpos anticancerígenos com fixação de complemento reduzida |
-
2005
- 2005-01-18 PT PT05701002T patent/PT1706428E/pt unknown
- 2005-01-18 ES ES05701002T patent/ES2330860T3/es active Active
- 2005-01-18 WO PCT/EP2005/000428 patent/WO2005070967A2/en active Application Filing
- 2005-01-18 DE DE602005016773T patent/DE602005016773D1/de active Active
- 2005-01-18 PL PL05701002T patent/PL1706428T3/pl unknown
- 2005-01-18 EP EP05701002A patent/EP1706428B1/de active Active
- 2005-01-18 DK DK05701002T patent/DK1706428T3/da active
- 2005-01-18 JP JP2006550009A patent/JP4987484B2/ja active Active
- 2005-01-18 AT AT05701002T patent/ATE443724T1/de active
- 2005-01-18 CA CA2553883A patent/CA2553883C/en active Active
- 2005-01-18 AU AU2005206277A patent/AU2005206277B2/en active Active
- 2005-01-21 US US11/040,071 patent/US7432357B2/en active Active
-
2008
- 2008-09-12 US US12/209,935 patent/US8835606B2/en active Active
-
2014
- 2014-09-05 US US14/478,753 patent/US9617349B2/en active Active
-
2017
- 2017-04-10 US US15/483,698 patent/US10017579B2/en active Active
-
2018
- 2018-07-03 US US16/026,846 patent/US10633452B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DE602005016773D1 (de) | 2009-11-05 |
CA2553883C (en) | 2013-04-02 |
WO2005070967A3 (en) | 2005-12-01 |
US20190031769A1 (en) | 2019-01-31 |
WO2005070967A2 (en) | 2005-08-04 |
AU2005206277B2 (en) | 2011-06-23 |
US9617349B2 (en) | 2017-04-11 |
US20150065691A1 (en) | 2015-03-05 |
US10017579B2 (en) | 2018-07-10 |
CA2553883A1 (en) | 2005-08-04 |
US7432357B2 (en) | 2008-10-07 |
ES2330860T3 (es) | 2009-12-16 |
PL1706428T3 (pl) | 2010-02-26 |
AU2005206277A1 (en) | 2005-08-04 |
PT1706428E (pt) | 2009-12-29 |
US8835606B2 (en) | 2014-09-16 |
US20050202021A1 (en) | 2005-09-15 |
JP4987484B2 (ja) | 2012-07-25 |
US20170210817A1 (en) | 2017-07-27 |
JP2007537719A (ja) | 2007-12-27 |
EP1706428A2 (de) | 2006-10-04 |
US10633452B2 (en) | 2020-04-28 |
US20090148441A1 (en) | 2009-06-11 |
DK1706428T3 (da) | 2009-11-30 |
EP1706428B1 (de) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE443724T1 (de) | Antikrebs-antikörper mit reduzierter komplementfixierung | |
PH12015500550A1 (en) | Anti-notch1 nrr antibodies and methods using same | |
MY150531A (en) | Anti-cd79b antibodies and immunoconjugates and methods of use | |
MY177062A (en) | Cd37-binding molecules and immunoconjugates thereof | |
MX2010003013A (es) | Inhibicion de angiogenesis. | |
MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
RU2448096C3 (ru) | Диарилгидантоины | |
ATE526987T1 (de) | Dr5-antikörper und deren verwendung | |
ATE459653T1 (de) | Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
MX2020012091A (es) | Composiciones anti-cd24 y usos de las mismas. | |
NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
MY146112A (en) | Long-term feed - cancer patient | |
TN2011000292A1 (en) | Amino pyrazole compound | |
EA201071248A1 (ru) | Дизамещенные фталазиновые антагонисты пути hedgehog | |
SI1572087T1 (sl) | Protitelesa proti antigenu tmeff2 raka in njihovauporaba | |
UA102115C2 (ru) | Дизамещенные фталазиновые антагонисты сигнального пути hedgehog | |
PH12021550120A1 (en) | Chimeric receptors to steap1 and methods of use thereof | |
SA519401424B1 (ar) | Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها | |
ATE435647T1 (de) | Rutheniumkomplexe zur krebsbehandlung | |
MXPA05008902A (es) | Soluciones de drogas en mentol. | |
TW200613604A (en) | Preparation of fabrics having lotus leaf effect and fabrics having lotus leaf effect | |
NZ593169A (en) | Anticancer compounds | |
WO2020102243A3 (en) | In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors | |
BRPI0515533A (pt) | forma de dosagem estável de derivados de fenilalanina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1706428 Country of ref document: EP |